OS Benefit Seen in Nonsquamous NSCLC With Triplet Regimen in IMpower130
October 23rd 2018Results from the phase III IMpower130 trial demonstrated a statistically significant improvement in both progression-free survival and overall survival with a triplet regimen of atezolizumab, carboplatin, and nab-paclitaxel compared with chemotherapy alone in patients with previously untreated stage IV nonsquamous non–small cell lung cancer.
Read More
Late-Breaking Research Supports Standard Cisplatin in HPV+ Oropharyngeal Cancer
October 23rd 2018Cisplatin plus radiotherapy improved overall survival compared with cetuximab plus radiotherapy in patients with HPV-positive oropharyngeal cancer, according to late-breaking research from the De-ESCALaTE HPV trial presented at the 2018 ESMO Congress.<sup> </sup>Results from this trial support the use of chemoradiotherapy as the standard of care for treatment in this patient population.
Read More
Entrectinib Induces Responses Across Multiple Tumor Types
October 22nd 2018Among patients with advanced solid tumors associated with <em>NTRK</em> gene fusions, more than half had responses to the small-molecule inhibitor entrectinib, according to an integrated analysis of 3 clinical trials presented at the 2018 ESMO Annual Congress.
Read More
Rucaparib Induces Responses in Nearly Half of Men With BRCA+ mCRPC
October 22nd 2018Among men in the ongoing phase II TRITON2 trial with BRCA1/2 alterations, 51% had a confirmed prostate-specific antigen response to rucaparib (Rubraca), according to preliminary data reported in a poster presentation by Wassim Abida, MD, PhD, and colleagues at the 2018 ESMO Congress.
Read More
Larotrectinib Induces 80% ORR in Advanced NTRK+ Solid Tumors
October 22nd 2018Larotrectinib induced an objective response rate of 80% in patients with advanced solid tumors who harbored <em>NTRK </em>gene fusions, according to results pooled from 3 small trials of the TRK inhibitor. Results were presented during the 2018 ESMO Congress.
Read More
Phase II Results of the GEOMETRY Mono-1 Study in NSCLC
October 21st 2018Juergen Wolf, MD, medical director, Center for Integrated Oncology (CIO) at the University Hospital Cologne, discusses the phase II findings of the GEOMETRY mono-1 study in patients with MET exon 14-mutated advanced non-small cell lung cancer.
Watch
SOLAR-1 Trial Results Demonstrate a Benefit for Genomic Testing in Breast Cancer
October 21st 2018Lead investigator Fabrice André, MD, PhD, said findings from the SOLAR-1 trial are the first to show benefit in a genomic subgroup of patients with breast cancer and could open the door for genomic testing in breast cancer.
Read More
Immunotherapy/TKI Combo Induces Favorable Findings in First-Line RCC
October 21st 2018A combination of an immune checkpoint inhibitor and a VEGF inhibitor, avelumab and axitinib, induced 2-fold higher objective response rates compared with sunitinib in patients with treatment-naïve advanced renal cell carcinoma, regardless of their PD-L1 expression. Progression-free survival was also significantly improved over sunitinib, according to findings from the phase III JAVELIN Renal 101 trial presented at the 2018 ESMO Congress.
Read More
PALOMA-3 Analysis Finds Improved OS in Pretreated HR+/HER2- Breast Cancer
October 21st 2018In results from an analysis of the phase III PALOMA-3 trial, patients with hormone receptor-positive, HER2-negative advanced breast cancer who had progressed or relapsed on prior endocrine therapy achieved a clinically meaningful benefit in overall survival from the combination of palbociclib plus fulvestrant.
Read More
No Survival Benefit Found When Radium-223 is Added to Abiraterone in mCRPC
October 20th 2018According to a presentation from the ERA 223 trial atthe 2018 ESMO Congress, no improvements in survival endpoints were seen with the addition of radium-223 dichloride to abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer.
Read More
Frontline Atezolizumab and Nab-Paclitaxel Demonstrate PFS Benefit in PD-L1+ mTNBC
October 20th 2018The combination of atezolizumab and nab-paclitaxel demonstrated a 2.5-month benefit in progression-free survival over nab-paclitaxel alone in patients with PD-L1–positive metastatic triple-negative breast cancer, according to findings of the phase III IMpassion130 trial presented at the 2018 ESMO Congress.
Read More
Presence of MET, EGFR C797S Mutations Linked With Osimertinib Resistance in NSCLC
October 20th 2018Patients with <em>EGFR</em>-mutant non–small cell lung cancer who had <em>MET</em> amplification and <em>EGFR</em> C797S mutations were most likely to have resistance to first-line treatment with osimertinib (Tagrisso), according to preliminary findings presented at the 2018 ESMO Congress.
Read More
Relapsed/Refractory MCL Landscape Continues to Evolve
September 15th 2018Mantle cell lymphoma remains an incurable disease, but according to Michael Wang, MD, it is becoming one of the most dynamic fields in oncology. In a presentation during the 2018 SOHO Annual Meeting, Wang recapped some of the biggest advancements in relapsed/refractory MCL, as well as the promise for novel therapies in this setting.
Read More
Heterogeneous Features Found in Analysis of Triple-Negative Myelofibrosis
September 15th 2018Triple-negative myelofibrosis makes up 10% to 15% of patients with myelofibrosis, but it is associated with higher rates of leukemic transformation and poorer survival. Investigators at the University of Michigan set out to better understand the disease and found that the clinical, cytogenetic, and molecular features of triple-negative myelofibrosis were heterogeneous.
Read More
The Importance of Intervention in Chronic Phase Myelofibrosis
September 15th 2018Srdan Verstovsek, MD, PhD, professor in the Department of Leukemia and director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the importance of intervention in chronic phase myelofibrosis.<br />
Watch
Selinexor/Dexamethasone Combo Shows Promising Activity in Penta-Refractory Myeloma
September 15th 2018The combination of selinexor and dexamethasone induced an overall response rate of 26.2% and a median overall survival of 8.6 months in patients with penta-refractory multiple myeloma, according to phase IIb results presented at the 2018 SOHO Annual Meeting.
Read More
Investigators Working to Improve Cure Rate in DLBCL
September 14th 2018Despite decades of drug development and a deepening understanding of the biology of diffuse large B-cell lymphoma, physicians haven’t seen much improvement in cure rates, Thomas E. Witzig, MD, said during a presentation at the 2018 SOHO Annual Meeting.
Read More
Safety of Carfilzomib Combinations Confirmed in Multiple Myeloma
September 14th 2018Consistent benefit was seen with carfilzomib (Kyprolis)-based regimens across subgroups of patients with multiple myeloma in the ASPIRE and ENDEAVOR trials, according to updated safety data reported at the 2018 SOHO Annual Meeting.
Read More
Adding the combination of venetoclax (Venclexta) and navitoclax (ABT-263) to chemotherapy induced an objective response rate of 66.7% in adults with relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma, according to results from a small phase I study presented at the 2018 SOHO Annual Meeting.
Read More
Germline Predisposition Explains MDS Etiology in Some Pediatric Patients
September 13th 2018Predisposition to forms of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in pediatric patients can be caused by either classical inherited bone marrow failure syndromes or recently discovered genetic predisposition syndrome with autosomal dominant inheritance, Marcin Wlodarski, MD, explained.
Read More
Resistance to Hydroxyurea Spurs Investigators to Seek Further Treatments in PV
September 13th 2018Hydroxyurea has been the primary treatment for polycythemia vera for decades and it works for the majority of patients, said Abdulraheem Yacoub, MD. However, there is a subset of patients who develop resistance or intolerance to hydroxyurea, and investigators are working to find a solution for those patients.
Read More
Ruxolitinib May Prove Beneficial in Combination for Myelofibrosis
September 13th 2018Ruxolitinib (Jakafi) is the only FDA-approved agent for the treatment of patients with myelofibrosis, making resistance to this agent a particularly difficult treatment challenge. Combinations with ruxolitinib may reinvigorate the impact of the JAK inhibitor in relapsed, progressive, or intolerant patients, explained Robyn M. Scherber, MD, MPH, in a presentation at the 2018 SOHO Annual Meeting.
Read More